Generic drugmaker Aurobindo Pharma called off the company’s $1 billion acquisition plans for multiple assets owned by Sandoz after failing to secure approval from the Federal Trade Commission.

The U.S. Food and Drug Administration is requesting makers of all versions of the heartburn drug Zantac to remove the products from the market immediately due to the presence of a probable carcinogen.

Shares of Amarin Corporation were down more than 70 percent in trading after a judge ruled that generic companies can go ahead and seek approval of generic versions of the drug manufacturer’s heart disease drug Vascepa.

Dr. Reddy’s Laboratories’ Foram Vaishnav discusses the role and impact of pharmacovigilance in the pharmaceutical industry.

The Bloc’s Dan Sontupe explores why the failure to educate patients about their conditions and treatment plans is a far bigger driver of healthcare costs than the price of prescription drugs.

U.S. researchers, following the lead of scientists in other countries, launched studies to see whether widely available, low-cost generic drugs can be used to help treat the illness caused by the new coronavirus.

A cheaper HIV prevention pill is going on sale in the United States, but experts say the price drop will not help as many people if doctors instead prescribe a newer, more expensive brand-name drug.

Less than a year after Sandoz, the generics arm of Novartis, vowed to fight allegations of being involved in a scheme to manipulate the price of generic drugs along with other drugmakers, the company changed course and agreed to pay a $195 million penalty to the U.S. government.

Mallinckrodt announced a $1.6 billion opioid settlement that will put the company’s generics business into bankruptcy.

Hector Armando Kellum, a former senior executive with the Novartis subsidiary Sandoz, pleaded guilty for his role in a price-fixing scheme for generic drugs developed by his company.